Larimar Therapeutics Q4 net loss widens on higher R&D costs

Larimar Therapeutics

19/03/2026 11:08

((This story was generated using AI and automation, please see
disclaimer https://bit.ly/rtrsnai))
    
    Overview
  
    * US biotech firm's Q4 net loss widened, driven by higher R&D expenses for nomlabofusp
    * Company completed $115 mln public offering in Feb 2026, extending cash runway into Q2 2027
    * FDA granted Breakthrough Therapy Designation for nomlabofusp in adults and children with FA

    
    Outlook
  
    * Larimar plans to report topline open label study data in Q2 2026
    * Company expects to initiate screening for global Phase 3 study in Q2 2026
    * Larimar targets BLA submission seeking accelerated approval in June 2026; U.S. launch first-half 2027, if approved

    
    Result Drivers
  
    * NOMLABOFUSP MANUFACTURING COSTS - Higher Q4 R&D expenses were mainly due to increased nomlabofusp manufacturing costs, including process qualification and scale up activities
    * CLINICAL AND REGULATORY SPENDING - Additional increases came from higher costs for ongoing clinical studies, consulting fees for quality, clinical, and regulatory activities, and personnel expenses
    * LOWER INTEREST INCOME - Decrease in other income was mainly due to lower interest yields and lower average investable cash balances

    
Company press release:  ID:nGNXbPqYrY 
    
    Key Details
  
                               
                               
 Metric    Beat/Mis  Actual    Consensu
           s                   s
                               Estimate
                               
                               
 Q4 EPS              -$0.73     
 Q4 Net              -$62.50    
 Income              mln       
 Q4                  -$64.02    
 Income              mln       
 From                          
 Operatio                      
 ns                            
 Q4                  $64.02     
 Operatin            mln       
 g                             
 Expenses                      
    
    Analyst Coverage
  
    * The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
    * The average consensus recommendation for the biotechnology & medical research peer group is "buy."
    * Wall Street's median 12-month price target for Larimar Therapeutics Inc is $16.00, about 272.1% above its March 18 closing price of $4.30

    
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)